Inception Lab,Artificial Intelligence Computer Diagnosis Research Lab in Korea, will receive an innovation award at CES 2024 in Las Vegas, USA, scheduled for January next year.
The Consumer Technology Association (CTA), the organizer of CES, evaluates and awards innovation prizes to outstanding products and services in technology, design, and other categories by reviewing innovative technological products from around the world before the exhibition.
Inception Lab, founded by Park Eun-bin, has received technology transfers for seven core technologies from the university. It has evolved into a digital healthcare and Alzheimer's electronic drug specialized company, with all researchers being alumni of Keimyung University.
In preparation for the era of super-aging, Inception Lab developed 'Inception ONE,' a Theragnosis (Therapy + Diagnosis) patch for elderly bedsores. This innovation has earned the company recognition in the digital health sector at CES 2024.
'Inception ONE' is a digital electronic patch that, when easily applied to areas suspected of bedsores in the elderly, automatically diagnoses bedsores using artificial intelligence and provides optimal treatment. It has been praised for digitizing the step-by-step diagnosis of bedsores, traditionally dependent on visual inspection, and optimizing bedsores treatment with innovative biophotonics technology.
'Inception ONE' has also secured safety based on risk management according to the IEC62366 international standard for medical devices through the Human Factor ICC usability evaluation research center of the Industry-Academia Collaboration Foundation LINC3.0. The company is preparing for overseas exports.
Currently, Inception Lab is conducting large-scale clinical trials with over 500 bedsores patients in various domestic institutions and has received purchase requests from local hospitals in the United States and Japan.
Park Eun-bin, a doctoral candidate in the Department of Biomedical Engineering and CEO of Inception Lab, stated, "Based on continuous innovation in digital diagnostic and therapeutic technology, we will create steady achievements through synergy between the super-aging and digital healthcare industries. At the same time, we will globally promote Keimyung University's outstanding research and development results."